SG10201605350UA - Compositions and Methods for the Treatment of Hepatic Diseases and Disorders - Google Patents
Compositions and Methods for the Treatment of Hepatic Diseases and DisordersInfo
- Publication number
- SG10201605350UA SG10201605350UA SG10201605350UA SG10201605350UA SG10201605350UA SG 10201605350U A SG10201605350U A SG 10201605350UA SG 10201605350U A SG10201605350U A SG 10201605350UA SG 10201605350U A SG10201605350U A SG 10201605350UA SG 10201605350U A SG10201605350U A SG 10201605350UA
- Authority
- SG
- Singapore
- Prior art keywords
- disorders
- compositions
- treatment
- methods
- hepatic diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21043—Classical-complement-pathway C3/C5 convertase (3.4.21.43)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
- A61K9/0058—Chewing gums
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biotechnology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261586975P | 2012-01-16 | 2012-01-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201605350UA true SG10201605350UA (en) | 2016-08-30 |
Family
ID=48799623
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202013014RA SG10202013014RA (en) | 2012-01-16 | 2013-01-16 | Compositions and Methods for the Treatment of Hepatic Diseases and Disorders |
| SG11201402650RA SG11201402650RA (en) | 2012-01-16 | 2013-01-16 | Compositions and methods for the treatment of hepatic diseases and disorders |
| SG10201605350UA SG10201605350UA (en) | 2012-01-16 | 2013-01-16 | Compositions and Methods for the Treatment of Hepatic Diseases and Disorders |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202013014RA SG10202013014RA (en) | 2012-01-16 | 2013-01-16 | Compositions and Methods for the Treatment of Hepatic Diseases and Disorders |
| SG11201402650RA SG11201402650RA (en) | 2012-01-16 | 2013-01-16 | Compositions and methods for the treatment of hepatic diseases and disorders |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US9713630B2 (en) |
| EP (1) | EP2804613A4 (en) |
| JP (1) | JP6632802B2 (en) |
| KR (3) | KR20200106088A (en) |
| CN (2) | CN104144693A (en) |
| AP (1) | AP2014007804A0 (en) |
| AU (2) | AU2013209887B2 (en) |
| BR (1) | BR112014016389A8 (en) |
| CA (2) | CA3208225A1 (en) |
| CR (1) | CR20140342A (en) |
| EA (1) | EA201491081A1 (en) |
| HK (1) | HK1198909A1 (en) |
| IL (1) | IL233639B (en) |
| NI (1) | NI201400076A (en) |
| NZ (1) | NZ625592A (en) |
| PE (1) | PE20142295A1 (en) |
| PH (1) | PH12014501620A1 (en) |
| SG (3) | SG10202013014RA (en) |
| WO (1) | WO2013109635A1 (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10202013014RA (en) | 2012-01-16 | 2021-02-25 | Mckenna Elizabeth | Compositions and Methods for the Treatment of Hepatic Diseases and Disorders |
| US20170232047A1 (en) * | 2012-01-16 | 2017-08-17 | Elizabeth McKenna | Control of Cellular Redox Levels |
| EP2898073A4 (en) * | 2012-09-21 | 2016-03-23 | Elizabeth Mckenna | Naturally occurring cpg oligonucleotide compositions and therapeutic applications thereof |
| CN105658226B (en) * | 2013-08-16 | 2019-05-14 | 港大科桥有限公司 | Use the method and composition of probiotics agents treatment cancer |
| RU2017127597A (en) | 2015-01-23 | 2019-02-25 | Темпл Юнивёрсити-Оф Дзе Коммонвелс Систем Оф Хайе Эдьюкейшен | APPLICATION OF SHORT-FATTY FATTY ACIDS FOR THE PREVENTION OF CANCER |
| KR20170032815A (en) * | 2015-09-15 | 2017-03-23 | 경희대학교 산학협력단 | Novel lactic acid bacteria and composition for preventing, improving or treating neurodegenerative diseases or cognitive dysfunction |
| AU2016352986A1 (en) * | 2015-11-10 | 2018-06-28 | Elizabeth Mckenna | Control of cellular redox levels |
| US20170143972A1 (en) * | 2015-11-19 | 2017-05-25 | Boston Scientific Neuromodulation Corporation | Neuromodulation for neuroinflammation treatments with parameters controlled using biomarkers |
| CN107080755A (en) * | 2017-04-28 | 2017-08-22 | 青岛东海药业有限公司 | Application of the bacillus coagulans in prevention or treatment COPD preparation is prepared |
| RU2764639C1 (en) * | 2018-02-02 | 2022-01-19 | Кобиолабс, Инк. | Lactobacillus plantarum strain kbl396 and application thereof |
| RU2696773C1 (en) * | 2018-08-13 | 2019-08-06 | Алексей Николаевич Осинцев | Method for producing a medicinal preparation of peptide nature with controlled and sequential release |
| CN110694069B (en) * | 2019-11-08 | 2022-02-25 | 重庆医科大学附属第二医院 | Medicine for preventing and treating fulminant hepatitis |
| CN110898063A (en) * | 2019-12-06 | 2020-03-24 | 湘北威尔曼制药股份有限公司 | New indication of drug combination of piperacillin and sulbactam for treating bacterial infection and hepatitis B |
| CN111494431B (en) * | 2020-04-28 | 2021-06-22 | 苏州大学 | Application of probiotics in preparation of preparation for treating liver diseases |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3806290A (en) | 1972-07-12 | 1974-04-23 | Warner Lambert Co | Apparatus for center-filled chewing gum |
| US4322405A (en) | 1981-04-06 | 1982-03-30 | Laboratoires Om Societe Anonyme | Method for treating rheumatoid arthritis |
| JPH04264034A (en) * | 1991-02-18 | 1992-09-18 | Snow Brand Milk Prod Co Ltd | Agent for suppressing lipid peroxide in living body |
| US5716615A (en) | 1992-02-10 | 1998-02-10 | Renata Maria Anna Cavaliere Vesely | Dietary and pharmaceutical compositions containing lyophilized lactic bacteria, their preparation and use |
| IT1254210B (en) | 1992-02-10 | 1995-09-14 | Simone Claudio De | DIETARY AND / OR PHARMACEUTICAL COMPOSITIONS BASED ON LYOPHILIZED LACTIC BACTERIA, THEIR PREPARATION AND USE |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| CA2194761C (en) | 1994-07-15 | 2006-12-19 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
| US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| IT1283225B1 (en) | 1996-03-11 | 1998-04-16 | Renata Maria Anna Ve Cavaliere | STRAINS OF BACTERIA, PHARMACEUTICAL COMPOSITION CONTAINING ONE OR MORE OF SUCH STRAINS AND USE OF THE SAME FOR THE PREVENTION AND THERAPY OF |
| JPH09301878A (en) | 1996-05-13 | 1997-11-25 | Youshindou:Kk | Tumor growth suppressing agent |
| JPH09301877A (en) * | 1996-05-13 | 1997-11-25 | Youshindou:Kk | Agent for treatment and prevention of hepatitis |
| AR022986A1 (en) | 1996-08-12 | 2002-09-04 | Gist Brocades Bv | PRODUCTION AND USE OF COMPOSITIONS THAT INCLUDE HIGH CONCENTRATIONS OF VITAMIN B12 ACTIVITY |
| US6214806B1 (en) | 1997-02-28 | 2001-04-10 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CPC dinucleotide in the treatment of LPS-associated disorders |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| JP5087758B2 (en) | 1997-03-10 | 2012-12-05 | オタワ ホスピタル リサーチ インスティチュート | Use of nucleic acids containing unmethylated CpG dinucleotides as adjuvants |
| WO1998052581A1 (en) | 1997-05-20 | 1998-11-26 | Ottawa Civic Hospital Loeb Research Institute | Vectors and methods for immunization or therapeutic protocols |
| US6281191B1 (en) * | 1997-12-29 | 2001-08-28 | Vladimir I. Slesarev | Compositions and methods for treating hepatitis-C |
| JP2002510644A (en) | 1998-04-03 | 2002-04-09 | ユニバーシティ オブ アイオワ リサーチ ファウンデーション | Methods and products for immune system stimulation using immunotherapeutic oligonucleotides and cytokines |
| JP4074006B2 (en) | 1998-06-24 | 2008-04-09 | アサマ化成株式会社 | Method for producing IgE antibody production inhibitor and food using the same |
| EP1178118A1 (en) | 2000-08-02 | 2002-02-06 | Dsm N.V. | Isolation of microbial oils |
| CA2440069A1 (en) | 2001-03-05 | 2002-09-12 | Ortho-Mcneil Pharmaceutical, Inc. | Taste masked pharmaceutical compositions |
| JP3853673B2 (en) * | 2001-03-09 | 2006-12-06 | 森永乳業株式会社 | Treatment for chronic hepatitis C |
| NZ552377A (en) | 2001-08-17 | 2008-08-29 | Coley Pharm Gmbh | Combination motif immune stimulatory oligonucleotides with improved activity |
| US20030119774A1 (en) | 2001-09-25 | 2003-06-26 | Marianna Foldvari | Compositions and methods for stimulating an immune response |
| US7838026B2 (en) | 2001-09-28 | 2010-11-23 | Mcneil-Ppc, Inc. | Burst-release polymer composition and dosage forms comprising the same |
| GB0203306D0 (en) | 2002-02-12 | 2002-03-27 | Norferm Da | Method |
| US20060228326A1 (en) | 2002-10-22 | 2006-10-12 | Fidler Isaiah J | Active specific immunotherapy of cancer metastasis |
| BR0315937A (en) | 2002-11-01 | 2005-09-13 | Viropharma Inc | A compound, composition for the prophylaxis or treatment of viral infections, and a method for the prophylaxis or treatment of hepatitis c infections and diseases associated with such infections in a living host. |
| WO2005024005A1 (en) | 2003-09-03 | 2005-03-17 | Intralytix, Inc. | Novel salmonella bacteriophage and uses thereof |
| JP3976742B2 (en) | 2004-02-27 | 2007-09-19 | 江守商事株式会社 | Immunostimulatory oligonucleotides that induce interferon alpha |
| JP2005247780A (en) | 2004-03-05 | 2005-09-15 | Masakazu Maruyama | Viral hepatitis-treating agent |
| US8182849B2 (en) * | 2005-02-23 | 2012-05-22 | Otsuka Pharmaceutical Co., Ltd. | Fermented tea beverage and tea beverage |
| EA200870001A1 (en) | 2005-05-12 | 2009-10-30 | Мартек Байосайенсиз Корпорейшн | HYDROLISATE BIOMASS, ITS APPLICATION AND MANUFACTURE |
| JPWO2007013613A1 (en) | 2005-07-29 | 2009-02-12 | サントリー株式会社 | Composition comprising fucoidan or fucoidan hydrolysis product and immunostimulatory material |
| DK2405002T3 (en) | 2006-02-15 | 2015-01-05 | Adiutide Pharmaceuticals Gmbh | Compositions and methods for oligonukleotidformuleringer |
| EP1872792A1 (en) | 2006-06-29 | 2008-01-02 | Biotech Tools S.A. | A method for the production of hydrolyzed allergen |
| US8304226B2 (en) | 2006-08-22 | 2012-11-06 | Carl Miller | Quality of life of hepatitis C patients with a formulation for administration to the oral mucosa including freeze dried lysate of selected Lactobacillus or Bifidobacterium species and N-acetyl D-glucosamine |
| US8007783B2 (en) | 2006-08-22 | 2011-08-30 | Carl Miller | Quality of life for hepatitis C patients with a formulation for administration to the oral mucosa including Lactobacillus delbrueckii subsp. bulgaricus and N-acetyl D-glucosamine |
| DE202008006598U1 (en) | 2008-04-11 | 2008-10-02 | Alk-Abelló A/S | Allergy vaccine formulation for mucosal administration |
| US8728461B2 (en) | 2008-07-04 | 2014-05-20 | Nippon Meat Packers, Inc. | Lactic acid bacterium having high immunoglobulin-A-inducing ability |
| KR20100008356A (en) | 2008-07-15 | 2010-01-25 | 한올제약주식회사 | Pharmaceutical formulation comprising channel blockers |
| CA2733249A1 (en) | 2008-09-04 | 2010-03-11 | Om Pharma | Immunomodulatory extracts from lactobacillus bacteria and methods of manufacturing and use thereof |
| BRPI1012170A2 (en) | 2009-05-20 | 2016-03-29 | Lingual Consegna Pty Ltd | formulation and / or sublingual and method for reducing the amount of active compound used to achieve an effect on a patient compared to a typical compound that is ingested. |
| JP6019492B2 (en) | 2009-08-28 | 2016-11-02 | 国立大学法人 千葉大学 | An antiallergic agent characterized by containing lactic acid bacteria and an antigenic substance and being administered into the oral cavity |
| FR2951377B1 (en) | 2009-10-21 | 2012-06-22 | Oreal | ASSOCIATION OF A PROBIOTIC LYSATE AND A C-GLYCOSIDE DERIVATIVE |
| GB201009273D0 (en) | 2010-06-03 | 2010-07-21 | Glaxosmithkline Biolog Sa | Novel vaccine |
| SG10202013014RA (en) | 2012-01-16 | 2021-02-25 | Mckenna Elizabeth | Compositions and Methods for the Treatment of Hepatic Diseases and Disorders |
| EP2898073A4 (en) | 2012-09-21 | 2016-03-23 | Elizabeth Mckenna | Naturally occurring cpg oligonucleotide compositions and therapeutic applications thereof |
-
2013
- 2013-01-16 SG SG10202013014RA patent/SG10202013014RA/en unknown
- 2013-01-16 CN CN201380004625.9A patent/CN104144693A/en active Pending
- 2013-01-16 CN CN202110783573.6A patent/CN113813294A/en active Pending
- 2013-01-16 KR KR1020207024890A patent/KR20200106088A/en not_active Application Discontinuation
- 2013-01-16 SG SG11201402650RA patent/SG11201402650RA/en unknown
- 2013-01-16 BR BR112014016389A patent/BR112014016389A8/en not_active Application Discontinuation
- 2013-01-16 PE PE2014001110A patent/PE20142295A1/en not_active Application Discontinuation
- 2013-01-16 US US13/743,194 patent/US9713630B2/en active Active
- 2013-01-16 AU AU2013209887A patent/AU2013209887B2/en active Active
- 2013-01-16 AP AP2014007804A patent/AP2014007804A0/en unknown
- 2013-01-16 KR KR1020147018038A patent/KR20140121818A/en not_active IP Right Cessation
- 2013-01-16 CA CA3208225A patent/CA3208225A1/en active Pending
- 2013-01-16 CA CA2860311A patent/CA2860311A1/en active Pending
- 2013-01-16 WO PCT/US2013/021752 patent/WO2013109635A1/en active Application Filing
- 2013-01-16 NZ NZ625592A patent/NZ625592A/en unknown
- 2013-01-16 KR KR1020227009659A patent/KR20220042485A/en not_active Application Discontinuation
- 2013-01-16 EA EA201491081A patent/EA201491081A1/en unknown
- 2013-01-16 EP EP13738189.3A patent/EP2804613A4/en active Pending
- 2013-01-16 SG SG10201605350UA patent/SG10201605350UA/en unknown
- 2013-01-16 JP JP2014552395A patent/JP6632802B2/en active Active
-
2014
- 2014-07-14 IL IL233639A patent/IL233639B/en active IP Right Grant
- 2014-07-14 PH PH12014501620A patent/PH12014501620A1/en unknown
- 2014-07-14 NI NI201400076A patent/NI201400076A/en unknown
- 2014-07-16 CR CR20140342A patent/CR20140342A/en unknown
- 2014-12-08 HK HK14112314.8A patent/HK1198909A1/en unknown
-
2017
- 2017-06-16 US US15/626,055 patent/US10149869B2/en active Active
-
2018
- 2018-10-28 US US16/172,825 patent/US11857577B2/en active Active
-
2021
- 2021-05-17 AU AU2021203147A patent/AU2021203147A1/en active Pending
-
2023
- 2023-01-06 US US18/151,205 patent/US20230372410A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL257581A (en) | Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| HK1214832A1 (en) | Compositions and methods for treatment of metabolic disorders and diseases | |
| HK1198909A1 (en) | Compositions and methods for the treatment of hepatic diseases and disorders | |
| HUE041553T2 (en) | Methods and compositions for the treatment of monogenic diseases | |
| HK1210968A1 (en) | Compositions and treatment for eye diseases and disorders | |
| IL239355A0 (en) | Gamma-hydroxybutyrate compositions and their use for the treatment of disorders | |
| IL225239A0 (en) | Compositions for the treatment of acne and related disorders | |
| EP2827856A4 (en) | Compounds and compositions for the treatment of muscular disorders | |
| ME03042B (en) | Compounds and compositions for the treatment of parasitic diseases | |
| PL2892556T3 (en) | Compositions and methods relating to the treatment of diseases | |
| EP2709632A4 (en) | Compositions and methods for the treatment of skin diseases | |
| HK1216721A1 (en) | Uses and methods for the treatment of liver diseases or conditions | |
| ZA201408060B (en) | Compositions and methods for the treatment of neurological disorders | |
| ZA201408061B (en) | Compositions and methods for the treatment of neurological disorders | |
| IL234616A0 (en) | Herbal composition for the treatment of metabolic disorders | |
| PL3079684T3 (en) | Compositions and methods for the treatment of diseases related to the renin-angiotensin-system | |
| ZA201408045B (en) | Compositions and methods for the treatment of inflammation and lipid disorders |